NASDAQ:SAVA

Cassava Sciences Stock Insider Trading

Healthcare > Biotechnology

Buy SAVA

*Your capital is at risk

$1.96

+0 (+0%)

At Close: Jun 03, 2026

Cassava Sciences Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 90.71. In total, the insiders bought 6.47M and sold 141.6K SAVA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	90.71
● Buy	6.47M shares
● Sell	141.6K shares
92% Buy Activity Weak Negative Correlation
Buy Signal High Confidence May 26, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 90.71. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (92% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
May 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Nicaise Claude Director	Director	26 500 Value: $55.9K
May 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Gussin Robert Z Director	Director	26 500 Value: $55.9K
May 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Gravier Pierre Director	Director	26 500 Value: $55.9K
May 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Anderson Robert Eugene Jr Director	Director	26 500 Value: $55.9K
Apr 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Schoen Eric Chief Financial Officer	C-Suite Officer	100 000 Value: $144.0K
Apr 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Barry Richard President & CEO	CEO / President	350 000 Value: $504.0K
Apr 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Nassif Freda Chief Business Officer	Officer	100 000 Value: $144.0K
Apr 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Cook Robert Christopher Chief Operating & Legal Office	Officer	100 000 Value: $144.0K
Apr 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Cook Robert Christopher Chief Operating & Legal Office	Officer	100 000 Value: $144.0K
Apr 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Nassif Freda Chief Business Officer	Officer	100 000 Value: $144.0K
Apr 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Barry Richard President & CEO	CEO / President	350 000 Value: $504.0K
Apr 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Schoen Eric Chief Financial Officer	C-Suite Officer	100 000 Value: $144.0K
Nov 29, 2024 Sell	Common Stock S-Sale	Kupiec James William Chief Medical Officer	Officer	4 000 Value: $15.5K
Nov 29, 2024 Buy	Common Stock M-Exempt	Schoen Eric Chief Financial Officer	C-Suite Officer	50 000 Value: $59.0K
Nov 29, 2024 Sell	Common Stock S-Sale	Schoen Eric Chief Financial Officer	C-Suite Officer	59 800 Value: $230.8K
Nov 29, 2024 Buy	Stock Option (Right to Buy) M-Exempt	Schoen Eric Chief Financial Officer	C-Suite Officer	50 000 Value: $59.0K
Nov 29, 2024 Sell	Common Stock S-Sale	Schoen Eric Chief Financial Officer	C-Suite Officer	2 000 Value: $8K
Nov 29, 2024 Sell	Common Stock S-Sale	Schoen Eric Chief Financial Officer	C-Suite Officer	2 000 Value: $8K
Nov 29, 2024 Buy	Stock Option (Right to Buy) M-Exempt	Schoen Eric Chief Financial Officer	C-Suite Officer	50 000 Value: $59.0K
Nov 29, 2024 Sell	Common Stock S-Sale	Schoen Eric Chief Financial Officer	C-Suite Officer	59 800 Value: $230.8K
Nov 29, 2024 Buy	Common Stock M-Exempt	Schoen Eric Chief Financial Officer	C-Suite Officer	50 000 Value: $59.0K
Nov 29, 2024 Sell	Common Stock S-Sale	Kupiec James William Chief Medical Officer	Officer	4 000 Value: $15.5K
Nov 18, 2024 Buy	Stock Option (Right to Buy) A-Award	Landen Jaren Chief Clinical Dev. Officer	Officer	85 000 Value: $2.38M
Nov 18, 2024 Buy	Stock Option (Right to Buy)	Landen Jaren Chief Clinical Dev. Officer	Officer	15 000 Value: $398.6K
Nov 18, 2024 Buy	Stock Option (Right to Buy) A-Award	Nassif Freda Chief Commercial Officer	Officer	100 000 Value: $2.80M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CASSAVA SCIENCES INC.

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sci...

Read Full Profile Here